Creutzfeldt-Jakob disease (CJD) is a rare and always-fatal brain disorder caused by misfolded proteins called prions. It affects roughly one to two people per million each year, strikes most often in the 60s and 70s, and typically kills within months of the first symptoms. What makes CJD unlike almost any other illness is its cause: not a bacterium, not a virus, but a normal human protein that has folded into the wrong shape and can force neighboring proteins to do the same, setting off a chain reaction that riddles the brain with microscopic holes.
What Prions Are and How They Destroy the Brain
Every healthy human brain contains a protein called PrP (prion protein). Its normal form sits on the surface of nerve cells and appears to play roles in cell signaling and copper transport, though researchers still debate its full job description. CJD begins when copies of this protein refold into an abnormal shape, designated PrPSc. The misfolded version is remarkably stable and resists the enzymes that normally break down and recycle old proteins. Worse, it acts as a template: when it contacts a normal PrP molecule, it can coax that molecule into adopting the same rogue shape. The result is a self-amplifying cascade that produces clumps of abnormal protein throughout the brain.
The damage these aggregates cause is not a single event but a collision of several processes happening at once. Spongiform degeneration, the hallmark sponge-like holes visible under a microscope, develops alongside widespread inflammation and the loss of connections between nerve cells.1PubMed Central. Mechanisms of neurodegeneration in prion diseases At the cellular level, neurons exposed to misfolded prion protein suffer severe stress in the endoplasmic reticulum, the compartment where proteins are normally folded and quality-checked. Calcium floods out of this compartment into the cell body, setting off a signaling chain that ultimately punches holes in the mitochondria and triggers programmed cell death.2PubMed Central. The intricate mechanisms of neurodegeneration in prion diseases Because prions spread through brain tissue rather than arriving all at once, different regions degrade at different rates, which is why patients can present with such varied symptoms depending on where the damage is concentrated.
The Different Forms of CJD
CJD is not one disease with one cause. It comes in several forms, and understanding which form a patient has matters for prognosis, genetic counseling, and public-health response.
Sporadic CJD
About 85 to 90 percent of cases are sporadic, meaning they appear without any known genetic mutation or external exposure. The prion protein misfolds spontaneously for reasons that remain unclear. Sporadic CJD (sCJD) itself is not a single entity. Scientists recognize six major subtypes based on two variables: the type of abnormal prion protein found in the brain (type 1 or type 2) and which version of the prion protein gene (PRNP) the patient carries at a specific position called codon 129, where a person can have methionine (M) or valine (V).3PubMed. Pathological spectrum of sporadic Creutzfeldt-Jakob disease The combination of MM1 and MV1 represents the “classic” form most clinicians picture when they think of CJD: rapid dementia, involuntary muscle jerks, and characteristic brain-wave patterns on an EEG. Other combinations produce different clinical pictures, including forms dominated by personality change, insomnia, or movement problems. Transmission studies in mice have confirmed that these subtypes correspond to at least four distinct prion strains, meaning the misfolded proteins themselves are structurally different.4PubMed Central. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties
Genetic CJD
Around 10 to 15 percent of CJD patients carry a mutation in the PRNP gene that makes their prion protein more prone to misfolding.5PubMed. Genetic Creutzfeldt-Jakob disease Inheritance follows an autosomal dominant pattern, meaning each child of a carrier has a 50 percent chance of inheriting the mutation, though not everyone who carries it will develop symptoms at the same age or with the same severity. The single most common mutation worldwide is the E200K substitution, which accounts for more than 70 percent of families with hereditary CJD.6PubMed Central. Ancestral origins and worldwide distribution of the PRNP 200K mutation causing familial Creutzfeldt-Jakob disease Clusters of genetic CJD have been documented in specific populations, including Libyan Jews and families in Slovakia and Chile, reflecting founder effects where one ancestral carrier’s descendants remained in a geographic area for generations.
Acquired Forms
A small fraction of cases are acquired from an external source of prions. Iatrogenic CJD results from medical procedures, most commonly dura mater grafts (patches of tissue used in brain surgery) and injections of growth hormone derived from human cadaver pituitary glands before synthetic versions became available.7PubMed. Iatrogenic Creutzfeldt-Jakob disease These cases have become exceedingly rare since the 1980s and 1990s, when the sources of contamination were identified and eliminated.
Variant CJD (vCJD) is the form that generated worldwide alarm in the 1990s. It is linked to eating beef products contaminated with the agent that causes bovine spongiform encephalopathy, commonly known as mad cow disease. Molecular strain typing and transmission experiments in mice support the conclusion that vCJD and BSE are caused by the same prion strain.8Clinical Microbiology Newsletter. Mad cow disease in the United States: an update on bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease Variant CJD tends to affect younger people, often in their 20s and 30s, and has a somewhat longer clinical course than the sporadic form, typically lasting over a year. The epidemic remained largely confined to the United Kingdom, where about 178 cases were recorded, along with a handful of cases in other countries.
What the Symptoms Look Like
CJD’s presentation depends heavily on which brain regions are hit first, but the overall arc is painfully consistent: a person goes from subtle neurological complaints to total incapacitation in weeks to months. In classic sporadic CJD, early symptoms often include rapidly worsening memory problems and difficulty with coordination. Personality changes, confusion, and visual disturbances are also common. As the disease progresses, patients develop myoclonus, the sudden involuntary jerking of muscles, along with stiffness, difficulty walking, and sometimes seizures.9PubMed Central. Slow to Respond: A Rapidly Progressive Case of Sporadic Creutzfeldt-Jakob Disease
The wide range of possible early symptoms creates a diagnostic challenge. Some patients first notice vision problems months before any cognitive decline, a presentation called the Heidenhain variant. In one documented case, a 72-year-old woman initially reported photophobia and blurring vision; within weeks her visual acuity had dropped to the level of perceiving only light, and she subsequently developed myoclonus and akinetic mutism before dying.10PubMed Central. Heidenhain Variant of Sporadic Creutzfeldt-Jakob Disease with a Variety of Visual Symptoms: A Case Report with Autopsy Study Other patients present primarily with psychiatric symptoms like anxiety, depression, or behavioral changes that initially look like a mental health disorder rather than a neurological one. The sheer breadth of early presentations is one reason CJD is often not suspected until the disease has advanced.
In the final stages, most forms of CJD converge on a state called akinetic mutism, where the patient can no longer move voluntarily or communicate.11PubMed Central. Multidisciplinary recommendations for palliative and supportive care in Creutzfeldt-Jakob disease and related disorders Some earlier symptoms, like behavioral disturbances and involuntary movements, can paradoxically diminish at this stage, not because the brain is recovering but because the neurological destruction has become so widespread that the patient lacks the capacity to manifest them.12Oxford Academic. Multidisciplinary recommendations for palliative and supportive care in Creutzfeldt-Jakob disease and related disorders
How CJD Is Diagnosed
Definitive diagnosis still requires examining brain tissue, either at autopsy or from a biopsy, for the presence of misfolded prion protein. But clinicians now have a suite of tools that can make a diagnosis highly probable during life.
Brain MRI is one of the most useful early tests. In sporadic CJD, diffusion-weighted imaging (DWI) sequences often show characteristic bright signals in the cortex and deep gray structures like the caudate nucleus and putamen.13PubMed. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol Variant CJD, by contrast, tends to light up the pulvinar, a structure at the back of the thalamus, producing the so-called “pulvinar sign.”14PubMed Central. Sporadic Creutzfeldt-Jakob disease: Brain MRI lesion features from 2 cases reports These imaging patterns are not unique to CJD, but in the right clinical context they significantly strengthen the diagnosis.
Spinal fluid testing provides another layer of evidence. The 14-3-3 protein, released when neurons are rapidly destroyed, was one of the earliest biomarkers used; it was detected in about 96 percent of CJD patients in an early validation study, with specificity around 96 percent among patients with other dementias.15PubMed. The 14-3-3 Brain Protein in Cerebrospinal Fluid as a Marker for Transmissible Spongiform Encephalopathies However, 14-3-3 can also be elevated after strokes and viral brain infections, which limits its usefulness when those conditions are in the differential. Total tau protein in spinal fluid has since been shown to predict CJD status at least as well as 14-3-3, and possibly better.16PubMed Central. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease
The most significant diagnostic advance in recent years is a test called RT-QuIC (real-time quaking-induced conversion). This assay works by giving any prion seeds present in a patient’s spinal fluid the chance to convert normal prion protein in a test tube, then detecting the resulting aggregates with a fluorescent dye. The test’s sensitivity is about 92 percent with a specificity of 100 percent, meaning a positive result essentially confirms the diagnosis.17Practical Neurology. RT-QuIC: a new test for sporadic CJD RT-QuIC has been incorporated into updated diagnostic criteria and has reduced the need for brain biopsy in many cases.
How Common Is CJD, and Is It Becoming More Frequent?
CJD is rare by any measure. A large surveillance study covering Europe, Australia, and Canada found an overall annual mortality of about 1.67 per million for all forms combined, and 1.39 per million for sporadic CJD specifically.18PubMed. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada In the United States, total reported CJD deaths rose from around 317 in 2007 to 502 in 2020, and the crude incidence climbed from roughly 1 per million to about 1.5 per million over that period.19JAMA Neurology. Change in Epidemiology of Creutzfeldt-Jakob Disease in the US, 2007-2020
That increase naturally raises the question: is CJD actually becoming more common, or are we just getting better at finding it? The answer leans toward the latter. After adjusting for the aging of the U.S. population, the rise in incidence among men was no longer statistically significant, and the rise among women, while still significant, was modest.20JAMA Neurology. Change in Epidemiology of Creutzfeldt-Jakob Disease in the US, 2007-2020 Better awareness among clinicians, wider use of MRI and RT-QuIC, and improved death-certificate coding all likely contribute to more cases being identified. The disease does peak in older age groups, so as the population ages, the absolute number of cases will naturally rise even if the underlying rate stays flat.
Why There Is No Cure and What Is Being Tried
No treatment has been shown to slow or stop CJD. The disease’s mechanism is stubbornly resistant to intervention: prions are not alive, so antibiotics and antivirals are irrelevant, and the misfolded protein aggregates are remarkably hard to clear once formed. Dozens of drugs have shown modest promise in cell cultures or animal models only to fail in patients.
The most closely watched effort right now is a clinical trial of a small interfering RNA (siRNA) that targets the messenger RNA encoding the prion protein, aiming to reduce how much PrP the brain produces in the first place. Developed by researchers at the Broad Institute and the University of Massachusetts Chan Medical School, this drug candidate works upstream of misfolding: if you cut the supply of the normal protein, there is less raw material for prions to recruit.21Broad Institute. Clinical trial of a prion disease drug candidate begins enrolling participants The trial is enrolling participants, but results are years away. Because CJD progresses so quickly, timing any intervention is a formidable obstacle: by the time a patient is diagnosed, substantial brain damage has usually already occurred.
In the absence of a cure, care is entirely palliative. Myoclonus can be managed with antiepileptic medications like levetiracetam or valproate. Agitation and delirium are treated with low-dose antipsychotics such as haloperidol, and sometimes benzodiazepines for episodes that do not respond. Excessive secretions, which become a problem as swallowing deteriorates, are addressed with scopolamine patches.22PubMed Central. Addressing the Unmet Needs of Patients With Rapidly Progressive Neurological Disease: A Case Report of Palliative Care in Creutzfeldt-Jakob Disease The goal shifts quickly from trying to maintain function to ensuring the patient is as comfortable as possible.
The Burden on Families and Caregivers
CJD is devastating not only for patients but for the people around them. The speed of decline is a major source of distress: families often go from first symptom to end-of-life planning in a matter of weeks, a timeline that barely allows for emotional processing, let alone logistical preparation. Research into caregiver experiences has identified three overlapping sources of suffering: the disease’s unique and frightening nature, gaps in clinical systems that leave families feeling unsupported, and the escalating demands of caregiving that quickly outstrip available resources.23PubMed Central. Developing neuropalliative care for sporadic Creutzfeldt-Jakob Disease
One recurring theme in caregiver accounts is the difficulty of the diagnostic journey itself. Because CJD is so rare, many clinicians have never seen a case. Patients may bounce between specialists for weeks before anyone considers a prion disease. Even after diagnosis, families often struggle to find healthcare providers who are familiar with CJD’s specific challenges, from infection-control precautions to the particular medications that help with myoclonus versus those that do not. Studies comparing caregiver burden across neurodegenerative diseases have found that CJD places an exceptionally high burden, possibly because of the psychiatric symptoms that can accompany it and the sheer pace of deterioration.24PubMed Central. Palliative care symptoms of people living with rapidly progressive prion diseases: a systematic review Multidisciplinary palliative care teams that include neurology, palliative medicine, social work, and psychology are considered best practice, but in reality many families never gain access to such coordinated support.
Public Health Concerns and Prion Resilience
Prions are not contagious in the everyday sense. You cannot catch CJD through casual contact, coughing, or sharing food. The routes of transmission that have been documented are all highly specific: transplanted tissue from an infected donor, contaminated surgical instruments that were not adequately decontaminated, and, in the case of variant CJD, consumption of BSE-contaminated beef. A small number of variant CJD cases have also been traced to blood transfusion.
The reason prions command such outsized public-health attention relative to their rarity is their extraordinary resistance to destruction. Standard hospital sterilization methods, the temperatures and chemical exposures that reliably kill bacteria, viruses, and fungi, do not fully inactivate prions.25PubMed Central. Recent Advances in Prion Inactivation by Plasma Sterilizer Instruments that contact high-risk tissues during neurosurgery on a CJD patient require specialized decontamination protocols involving concentrated sodium hydroxide or prolonged autoclaving at higher-than-normal temperatures, and in some cases are simply destroyed after use.
Blood-supply safety is another concern. Prions have been detected in both white blood cells and plasma, and leukoreduction, the standard process of filtering white cells out of donated blood, is likely not sufficient to eliminate the risk entirely.26PubMed. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France Current prevention relies mainly on screening donors: people who lived in the United Kingdom during the peak years of the BSE epidemic, for instance, were for many years deferred from donating blood in several countries. Some of these restrictions have been relaxed as the vCJD epidemic has waned, but the policies reflect how seriously public-health authorities take even a small theoretical risk when no reliable blood test for prion infection exists in asymptomatic donors.
CJD and Other Prion Diseases in Animals
Prion diseases are not unique to humans. Scrapie in sheep has been recognized for centuries, and BSE in cattle triggered the vCJD crisis. More recently, chronic wasting disease (CWD), a prion disease spreading through deer, elk, and moose populations in North America and parts of Scandinavia, has become a growing concern. CWD is highly transmissible among cervids and has reached prevalence rates above 30 percent in some herds. The key question is whether CWD prions can cross the species barrier into humans the way BSE prions did. So far, no confirmed case of human prion disease has been attributed to CWD, but laboratory experiments have shown that CWD prions can convert human prion protein under certain conditions, and surveillance is ongoing. Health agencies in affected regions advise hunters to have harvested animals tested and to avoid eating meat from animals that test positive.
The history of BSE teaches a cautionary lesson: the species barrier was once assumed to protect humans from cattle prions, until variant CJD proved otherwise. That precedent keeps researchers and public-health officials vigilant about CWD, even in the absence of a confirmed human case. Prion diseases move on long timescales. Incubation periods can stretch to decades, meaning any cross-species transmission event happening now might not become apparent for years.
How the Prion Concept Changed Biology
Before CJD and related diseases were understood, the idea that a protein alone, with no DNA or RNA, could be infectious struck most biologists as impossible. The diseases that would later be grouped as prion disorders were first described clinically in the early 1920s, but their cause remained a mystery for six decades.27PubMed Central. A brief history of prions Stanley Prusiner’s coining of the word “prion” in 1982 and the subsequent isolation of the infectious protein from diseased animals were met with fierce skepticism from researchers who could not accept a pathogen that lacked genetic material. Prusiner was awarded the Nobel Prize in 1997, and the prion concept has since expanded well beyond medicine: yeast biologists have found prion-like protein behavior in fungi, and elements of prion-like propagation have been implicated in other neurodegenerative diseases, including Alzheimer’s and Parkinson’s, where misfolded proteins appear to spread through the brain in a templated fashion. CJD remains the starkest and most lethal example, but the broader idea that proteins can carry and transmit biological information without nucleic acids has reshaped how scientists think about a wide range of diseases.